NovoCure Limited - Ordinary Shares (NVCR)

NovoCure (NASDAQ:NVCR) reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it raised full-year revenue and adjusted EBITDA guidance. Executive Chairman William Doyle said the qu

NovoCure (NASDAQ:NVCR) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to

AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.

Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.

Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.

This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

NovoCure (NVCR) Q1 2026 Earnings Transcript

NovoCure (NVCR) Q4 2025 Earnings Call Transcript

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

H.C. Wainwright raised the firm's price target on Novocure to $47 from $39 and kept a ‘Buy’ rating on the shares after the company announced FDA approval of Optune Pax.

The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of February 12, 2026. Introduction NovoCure Limited (NASDAQ: NVCR) stands as a unique outlier in the oncology landscape. Unlike the traditional pharmaceutical giants that dominate the space with [...]